Regeneron to Acquire Checkmate for $250M, Expanding Cancer I/O Pipeline
Regeneron Pharmaceuticals has agreed to acquire Checkmate Pharmaceuticals for approximately $250 million cash, the companies said, in a deal that expands the buyer’s immuno-oncology pipeline with Checkmate’s m…
Read guide →